Merck stock holds above key technical levels after FDA RSV filing news

Merck stock holds above key technical levels after FDA RSV filing news
Merck stock edges higher above $128

Merck said the FDA has accepted its filing related to RSV disease in a post on its official account. At the same time, Merck stock edges higher on the day, trading at $128.34.

MRK price prediction
24H 0.23%
€150.15
48H -0.01%
€149.78
7D -0.3%
€149.35
1M 4.74%
€156.9
3M 13.66%
€170.26
6M 2.97%
€154.25
12M 25.93%
€188.64
Current price: €149.8 0.75 0.50%
Closed 11/16
Daily range 149.30 Arrow from to Icon 151.05
Weekly range 144.60 Arrow from to Icon 156.20
Loading...

Highlights

  • The FDA has accepted Merck's regulatory filing for its RSV disease treatment, marking a key milestone in the company's drug pipeline.
  • Merck stock trades at $128.34, with the company valued at $308.9 billion and employing 73,000 people.
  • Merck stock displays a bullish technical outlook, with a 75% probability of upside and an expected trading range of $125.99 to $130.68 for the coming week.

The company itself posted that the FDA has accepted its filing related to RSV disease. The relevant detail is the regulatory milestone, which may hold importance for the company’s drug pipeline. Merck operates as a major drug manufacturer with a market value near $308.9 billion and employs 73,000 people. The post focuses on company activity linked to the regulatory landscape.

Stable posture as market favors broader bullish trend

Since the timing of the regulatory headline cannot be directly linked to the market move, it's not possible to attribute the price action in Merck stock to that event. Instead, the session showed a muted reaction, with price movements aligning with the broader bullish structure already present in the chart. Shares held above key levels including the Ichimoku Kijun at $127.61 and continued to track above the MA-20, MA-50, and MA-200. Stoch RSI remains in oversold territory, which limits room for further downside and helps support a stable posture.

Upside potential as traders monitor intraday breakout

To determine whether the market is starting to price in new regulatory developments, traders should look for confirmation around the recent intraday range, which stretched from $127.56 to $131.08—well above prior daily averages. The past move remained contained within a narrow band, but over the coming trading week, there is a 75% probability of upside versus a 25% chance to the downside, with an expected trading range of $125.99 to $130.68. A close above $131.47 would indicate buyers are pushing the narrative forward, while a drop below $127.61 would suggest the move is being faded. On the weekly chart, the longer-term picture for Merck stock stays constructive.

Earlier, analysts noted that Merck’s technical setup remained broadly bullish, with price action guided by support at key moving averages. The latest regulatory milestone adds a new dimension to the story, and short-term traders should monitor whether a move through $131.47 confirms upside momentum in the coming week.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.